Everest Medicines gets NMPA approval for Cardamyst NDA in adult PSVT
Everest Medicines Limited says China’s NMPA approved its Cardamyst (etripamil) NDA for treating PSVT in adults.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Everest Medicines gets NMPA approval for CARDAMYST in adult PSVT
Everest Medicines said China’s NMPA approved CARDAMYST (etripamil) to convert acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.
Everest Medicines gets China NMPA approval for CARDAMYST® in PSVT
Everest Medicines announced China’s NMPA approval of CARDAMYST® for converting acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.